CBR-470-2 (C007B-343234)

CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysisIn VitroCBR-470-2 (1-10 μM; 24 h) increases transcript levels of the NRF2-responsive genes NQO1 and HMOX1 in epidermal keratinocytes and dermal fibroblasts. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoCBR-470-2 (50 mg/kg; p.o. twice daily for 10 d) induces activation of NRF2 signaling in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/C mice (5-week old) are exposed to UVB Dosage: 50 mg/kg Administration: P.o. twice daily for 10 days Result: Resulted in comparable beneficial effects on erythema histological scores and total wounded area. Decreased epidermal thickness in response to UV exposure.Form:SolidIC50& Target:NRF2. Specification: 0.99 Molecular Formula: C12H13Cl2NO6S2 Molecular Weight: 402.27 PubChem CID: 155819525

UPC:

41181887

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

C650324-100mg

CAS:

2416095-00-4

Product Size:

100mg